<DOC>
	<DOCNO>NCT01074645</DOCNO>
	<brief_summary>Background : Reactivation hepatitis B well-characterized syndrome mark abrupt reappearance rise hepatitis B virus ( HBV ) DNA serum patient previously inactive resolve HBV infection . Reactivation spontaneous , commonly trigger cancer chemotherapy , immune suppression , alteration immune function . Spontaneous acute exacerbation chronic hepatitis B infection see cumulative probability 15±37 % 4 year follow-up.2 Significant number patient spontaneous acute exacerbation chronic hepatitis B may present high ALT level , jaundice liver failure.3 This condition define acute-on-chronic liver failure ( ACLF ) accord recent Asia-Pacific consensus recommendation . The short term prognosis patient spontaneous acute exacerbation chronic hepatitis B lead ACLF like presentation extremely poor , mortality 30-70 % different series.8,9,10 Liver transplantation definitive therapy available salvage group patient . However , readily available affordable . Another therapeutic option antiviral therapy limit data . The efficacy lamivudine evaluate compare historical control find beneficial.8,9,10 However , study Taiwan show survival benefit subgroup patient lamivudine baseline bilirubin 342 mmol/L ( 20 mg/dL ) .11 Tenofovir disoproxil fumarate ( TDF ) potent , rapidly act , oral acyclic nucleotide analogue , reverse transcriptase inhibitor show highly effective suppress hepatitis B virus replication.12 Tenofovir also show excellent activity HBV LAM- naïve LAM-resistant patients.13,14 . Its efficacy evaluate patient reactivation hepatitis B present ACLF Hypothesis : The investigator hypothesis Tenofovir reduces morbidity mortality patient Spontaneous reactivation hepatitis B reduce HBV DNA .</brief_summary>
	<brief_title>Randomized Controlled Trial Tenofovir Patients Reactivation Hepatitis B Presenting Acute Chronic Liver Failure</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Reactivation chronic hepatitis B characterize rise ALT level &gt; 5 time upper limit normal along HBV DNA level &gt; 105 copies/ml ( ~1.8x104 IU/ml ) present ACLF Acute hepatic insult Jaundice ( bilirubin ≥5 mg/dL ) coagulopathy ( INR &gt; 1.5 ) Complicated within 4 week ascites and/or encephalopathy patient previously diagnose undiagnosed chronic liver disease . Superinfection virus ( Hepatitis E , A , D C ) Coexistent hepatocellular carcinoma ( HCC ) Portal vein thrombosis Coexistent renal impairment Pregnancy Coinfection HIV infection Patients receive previous course antiviral Immunomodulator cytotoxic/immunosuppressive therapy chronic hepatitis illness within least precede 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Acute-on -chronic liver failure</keyword>
	<keyword>Reactivation hepatitis B</keyword>
	<keyword>Spontaneous reactivation chronic hepatitis B present acute-on-chronic liver failure</keyword>
</DOC>